Smart Oral Administration of Polydopamine‐Coated Nanodrugs for Efficient Attenuation of Radiation‐Induced Gastrointestinal Syndrome

Zhang, Yushuo; Wang, Lu; Xu, Meiyun; Zhao, Tongxin; Kuang, Liangju; Hua, Daoben

doi:10.1002/adhm.201901778

Cited by 24 publications

(16 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twelve before irradiation, the mice needed the following treatments: (1) the blank group (300 μL deionized water), (2) model group (300 μL deionized water), (3) montmorillonite group (8 mg medicinal montmorillonite added to 300 μL deionized water), and (4) TXA-MMT group (8 mg composite added to 300 μL deionized water). The mice was anesthetized by intraperitoneal injection of 1% (w/v) pentobarbital sodium (50 mg•kg -1 ) before irradiation and then fixed on the irradiation plate with shielding the rest of the abdominal irradiation with lead to avoid hematopoietic damage caused by radiation [32]. Apart from the normal group, mice was administered Co-60 radiation from the radiation source to both the model group and the administration group, with an absorbed dose of 14 Gy and a dose rate of 66.92 cGy•min -1 ; the animals were 3.0 m distant from the radiation source.…”

Section: Ionizing Radiation and Materials Interventionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Novel Tranexamic Acid/Montmorillonite Intercalation Composite, as a New Type of Hemostatic Material

Ma¹,

Sui

Yang³

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Radiation enteritis—clinically manifested as diarrhea, intestinal bleeding, and so on—is frequently caused when the body is exposed to radiation or radiotherapy because the intestine is radiation-sensitive as an abdominal organ. Therefore, strategies to modulate intestinal hemostasis had inspired an important research trend in the process of preventing and treating radiation enteritis. Based on the structural characteristics of montmorillonite (MMT) and the hemostatic drug tranexamic acid (TXA) which was used clinically to treat enteritis, the tranexamic acid-montmorillonite composite material (TXA-MMT) was prepared through intercalation composite technology. According to the analysis of FTIR, XRD, TG-DTG, SEM, and XRF, the prepared TXA-MMT was verified that tranexamic acid could intercalate into layers of montmorillonite. To evaluate the biocompatibility, two experiments were conducted by in vitro hemolysis and in vitro cytotoxicity experiments and results showed that TXA-MMT exhibited good visible biocompatibility. Activated partial thromboplastin time, prothrombin time, and in vitro clotting time were adopted to determine the hemostatic effect of TXA-MMT. Compared with other groups, TXA-MMT revealed a significant decrease in clotting time variations, APTT, and PT. In addition, to investigate the preventive effect of TXA-MMT by the intervention of radiation enteritis mice, inflammatory factors IL-1β, IL-6, and TNF-α and the content of endotoxin in the serum of mice were detected. It demonstrated that TXA-MMT reduced the levels of these factors. Besides, the expression and the pathological changes of the small intestine tissue of mice were relieved. Our findings suggests that TXA-MMT as a promising intercalation composite has a great potential for application in the field of intestinal hemostasis.

show abstract

Section: Ionizing Radiation and Materials Interventionmentioning

confidence: 99%

“…Then, the tissue was fixed with 4% formaldehyde and routinely dehydrated, and then, it was cut transversely into 5 μm thick sections and stained with hematoxylin-eosin (HE). Hence, its pathological changes can be observed under a light microscope [32][33][34].…”

Section: Ionizing Radiation and Materials Interventionmentioning

confidence: 99%

Evaluation of Novel Tranexamic Acid/Montmorillonite Intercalation Composite, as a New Type of Hemostatic Material

Ma¹,

Sui

Yang³

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In a previous review, we introduced many nanoradioprotectors. Thereafter, new nanoradioprotectors, such as ultrasmall Au‐MoS 2 clusters, [ 177 ] PVP‐coated PtPdMo nanocubes, [ 178 ] PtPd nanocrystals, [ 179 ] naturally derived PHA‐L protein NPs, [ 180 ] CeO 2 /Mn 3 O 4 nanocrystals, [ 57 ] pH‐triggered Mn clusters, [ 181 ] polydopamine@arginine–chitosan (thalidomide) nanodrugs, [ 58 ] Nb 2 C‐PVP nanosheets, [ 31 ] CNSI, [ 32 ] and the GLSO@P188/PEG400 nanosystem, [ 37 ] have emerged. Their emergence enriched the treatment pattern in the radioprotection field.…”

Section: Discussionmentioning

confidence: 99%

“…Nanomaterials have been reported to possess gastrointestinal tissue radioprotective abilities, and drug design has also been gradually optimized in recent years. [ 28,32,52–58 ] For example, in 2003, Guo et al. used the herpes simplex virus (HSV)‐1‐based vector to deliver human manganese superoxide dismutase (MnSOD) genes in the small intestine of mice to prevent radiation enteritis.…”

Section: Nanomaterials Design For Prevention and Treatment Of Various mentioning

confidence: 99%

Rational Design of Nanomaterials for Various Radiation‐Induced Diseases Prevention and Treatment

Xie

Zhao

Wang

et al. 2021

Adv Healthcare Materials

View full text Add to dashboard Cite

Radiation treatments often unfavorably damage neighboring healthy organs and cause a series of radiation sequelae, such as radiation‐induced hematopoietic system diseases, radiation‐induced gastrointestinal diseases, radiation‐induced lung diseases, and radiation‐induced skin diseases. Recently, emerging nanomaterials have exhibited good superiority for these radiation‐induced disease treatments. Given this background, the rational design principle of nanomaterials, which helps to optimize the therapeutic efficiency, has been an increasing need. Consequently, it is of great significance to perform a systematic summarization of the advances in this field, which can trigger the development of new high‐performance nanoradioprotectors with drug efficiency maximization. Herein, this review highlights the advances and perspectives in the rational design of nanomaterials for preventing and treating various common radiation‐induced diseases. Furthermore, the sources, clinical symptoms, and pathogenesis/injury mechanisms of these radiation‐induced diseases will also be introduced. Furthermore, current challenges and directions for future efforts in this field are also discussed.

show abstract

“…Active compounds can be coated with speci c materials to prepare nanoparticles, and these coating materials can help to promote and maintain the biological activity of the encapsulated compounds, facilitate sustained release, change the method of administration, improve drug utilization, reduce adverse reactions, and can be degraded and absorbed by the host [22,23]. When applied to oral vaccines, nanoparticles can protect drugs from degradation by gastrointestinal enzymes, improve the bioavailability of drugs, and enhance drug function [24,25]. CS is a natural amino polysaccharide resulting from the deacetylation of chitin and has high biodegradability and biocompatibility, making it useful in medicine, food, textiles, and so on [26,27].…”

Section: Discussionmentioning

confidence: 99%

Synthesis of Escherichia coli OmpA oral nanoparticles and evaluation of immune function against the main pathogenic bacteria of cow mastitis

Liu¹,

Sun²,

Wu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Escherichia coli is a main pathogenic bacteria that causes cow mastitis, a condition that results in huge economic losses. There is lack of orally delivered prevention for cow mastitis. The outer membrane protein A (OmpA) of E. coli is immunogenic and can be used in a vaccine. In the present study, OmpA was synthesized into nanoparticles (NP-OmpA) for oral delivery and prevention of cow mastitis.Methods: OmpA was purified with Ni-NTA flow resin and encapsulated with chitosan (CS) to prepare NP-OmpA nanoparticles. The gastrointestinal tract was simulated in vitro (PBS, pH 1.2) to measure the protein release rate. The optimal preparation conditions for NP-OmpA were determined by analyzing the concentrations of OmpA and CS, magnetic mixing speed, mixing time, and ratio of tripolyphosphate (TPP)/CS (W/W). NP-OmpA safety was detected by function factors and histopathological examination of livers and kidneys. Immune activity of NP-OmpA was determined using qRT-PCR to detect immune-related gene expression, leukocyte phagocytosis of Staphylococcus aureus, ELISA to detect antiserum titer and immune recognition of E. coli, and the organ index. The immune protection function of NP-OmpA was assessed by the protection rate of NP-OmpA to E. coli in mice, qRT-PCR for inflammation-related gene expression, assay kits for antioxidant factors, and visceral injury in the histopathological sections. Results: NP-OmpA nanoparticles had a nanodiameter of about 700 nm, loading efficiency (LE) of 79.27%, and loading capacity (LC) of 20.31%. The release rate was less than 50% in vitro. The optimal preparation conditions for NP-OmpA were OmpA protein concentration of 2 mg/mL, CS concentration of 5 mg/mL, TPP/CS (W/W) of 1:1, magnetic mixing speed of 150 r/min, and mixing time of 15 min. Histopathological sections and factors of uric acid (UA), creatinine (Cr), alanine aminotransferase (ALT), aspartate transaminase (AST), catalase (CAT), glutathione (GSH), and malondialdehyde (MDA) showed NP-OmpA was safe for mice liver and kidney. NP-OmpA could enhance the immune-related gene expression of IFN-γ and HSP70 in the spleen, liver, and kidney, and the leukocyte phagocytosis of S. aureus. The antiserum titer (1: 3200) was obtained from mice immunized with NP-OmpA, which had an immune recognition effect to E. coli. The immune protection rate of NP-OmpA was 71.43% (p < 0.05) to E. coli. NP-OmpA could down regulate the inflammation-related gene expression of TNF-a, IL-6, and IL-10 in the spleen, liver, and kidney, and the antioxidant factors MDA and SOD in the liver, and reduce the injury in mice liver and kidney induced by E. coli. Conclusion: A novel NP-OmpA nanoparticle was synthesized, and the optimal preparation conditions were determined. The nanoparticles were found to be safer and have better immune function. They are expected to induce a response that resists infection with the main pathogenic bacteria (E. coli) of cow mastitis.

show abstract

Smart Oral Administration of Polydopamine‐Coated Nanodrugs for Efficient Attenuation of Radiation‐Induced Gastrointestinal Syndrome

Cited by 24 publications

References 54 publications

Evaluation of Novel Tranexamic Acid/Montmorillonite Intercalation Composite, as a New Type of Hemostatic Material

Evaluation of Novel Tranexamic Acid/Montmorillonite Intercalation Composite, as a New Type of Hemostatic Material

Rational Design of Nanomaterials for Various Radiation‐Induced Diseases Prevention and Treatment

Synthesis of Escherichia coli OmpA oral nanoparticles and evaluation of immune function against the main pathogenic bacteria of cow mastitis

Contact Info

Product

Resources

About